-
+24 +1
Cheap Diabetes Drug Slashes Risk of Long COVID, Study Finds
People who took a cheap diabetes drug after testing positive for COVID-19 had a 40 percent lower risk of getting long COVID, a US-based study said Friday.
-
+16 +1
Drug Price Negotiation Is A Second-Best Fix. Here's What Will Really Work
As Democrats struggle to bring together 50 votes to pass the Build Back Better Act, a major sticking point with the legislation has emerged. That is, whether it should include provisions changing the law to allow Medicare to negotiate drug prices...
-
+15 +1
Ivermectin: How false science created a Covid 'miracle' drug
Thousands worldwide have taken ivermectin to fight Covid. But what's the evidence?
-
+15 +1
‘People need something to celebrate’: Bell-ringing pharmacist gives COVID-19 vaccine drive a shot in the arm
Kyro Maseh celebrates each vaccine given as a way to get us out of the pandemic. (Includes video)
-
+12 +1
Americans pay more for prescription drugs than anyone else. Can Amazon Pharmacy change that?
An Amazon Prime membership already gets you deals on retail goods, snappy deliveries and access to video-streaming content. Now, the e-commerce behemoth says it will also get you free two-day deliveries at the newly-announced Amazon Pharmacy, as well as savings on generic and brand-name medication.
-
+4 +1
Whoever invents a coronavirus vaccine will control the patent – and, importantly, who gets to use it
A unique challenge is emerging in the search for a COVID-19 vaccine: how to balance intellectual property rights with serving the public good. Unfortunately, very few pharmaceutical and biotechnology corporations are participating in the pledge.
-
+12 +1
Another Way In Which Patents Contributed To The Opioid Crisis: Hospitals Ordered Not To Use Better, Less Problematic Medicines
Two years ago, we wrote about a stunning (and horrifying) study that explained how patents deeply contributed to the opioid crisis. It described the lengths that drug companies -- including OxyContin maker Purdue Pharma -- went through to block any...
-
+14 +1
Hidden conflicts? Investigative report: How pharma money could bias FDA drug approvals
An investigative report uncovers little recognized and unpoliced potential conflicts of interest among those who serve on FDA advisory panels that review drugs. Some members of such panels are later receiving significant payments from either the makers of drugs they previously reviewed, or from competitors. This is happening despite the FDA's established system to identify possible financial conflicts of interest among those recruited for the drug advisory panels. The investigation analyzed records on the federal Open Payments website between 2013 and 2016. Of 107 physician advisors who voted on FDA advisory committees during this time, 26...
-
-1 +1
Free yourself from the needle: Biotech for diabetes - Jsb Conference
Even though the world is plagued with emerging diseases, there are a number of illnesses that have been known for quite a while, and yet, their contribution to the death toll is higher than their peers. The field of medicine is still struggling to provide a cure to these. One such disease is diabetes. Diabetes … Continue reading Free yourself from the needle: Biotech for diabetes
-
Current Event+14 +1
Five Manhattan Doctors Indicted For Accepting Bribes And Kickbacks From A Pharmaceutical Company In Exchange For Prescribing Powerful Fentanyl...
Geoffrey S. Berman, the United States Attorney for the Southern District of New York, and William F. Sweeney Jr., the Assistant Director-in-Charge of the New York Field Office of the Federal Bureau of Investigation (“FBI”), announced the unsealing today of an Indictment in Manhattan federal court charging five Manhattan doctors, GORDON FREEDMAN, JEFFREY GOLDSTEIN, TODD SCHLIFSTEIN, DIALECTI VOUDOURIS, and ALEXANDRU BURDUCEA, with participating in a scheme to receive bribes and kickbacks in the form of fees for sham educational programs (“Speaker Programs”) from a pharmaceutical company (“Pharma Company-1”) in exchange for...
-
+14 +1
The Myth of What’s Driving the Opioid Crisis
Doctor-prescribed painkillers are not the biggest threat.
-
+24 +1
Ending the Opioid Crisis
Trump finally declared mass opioid addiction a national emergency. But he won’t take on big pharma and the social roots of the crisis.
-
+15 +1
Walgreens scraps Rite Aid merger, will instead buy half its stores
Drugstore chain Walgreens Boots Alliance Inc (WBA.O) scrapped its deal to buy Rite Aid Corp (RAD.N) after failing to win antitrust approval, but said it would instead buy nearly half of the smaller rival's U.S. stores for $5.18 billion.
-
+31 +1
EpiPen maker faces revolt over exec's $98 million pay package
EpiPen maker Mylan is racing to put down a revolt from shareholders outraged by a $98 million pay package for its former CEO.
-
+1 +1
Big Pharma boss caught giving execs two middle fingers after they complain about EpiPen price gouging: report
Mylan is still facing public outrage over its decision to jack up EpiPen prices, but a new report from the New York Times claims that Mylan’s chairman isn’t worried about the backlash at all.
-
+16 +1
Mylan shareholders revolt, say directors’ greed has gone too far
Meanwhile, a new report suggests Mylan overcharged taxpayers by $1.27 billion. The investors were particularly critical of Chairman Robert Coury, who received more than $160 million in compensation in 2016
-
+1 +1
With a 10-day supply of opioids, 1 in 5 become long-term users
The longer a person uses opioids, the greater the risk of forming a deadly addiction. But just how long does it take to switch from being a short-term user—say, while you’re dealing with pain after a surgery—to a long-term, potentially problematic user? A few weeks? A month? According to a new study, that transition could take just a matter of days.
-
+15 +1
Marathon gets the Shkreli treatment from industry after $89K drug dust up
Public relations nightmare strikes just when drug makers try cleaning their image.
-
+8 +1
The Opioid Epidemic Is a Symptom of Toxic Greed
Our system of financing drug research gave the makers of OxyContin a multibillion-dollar incentive to ignore the risks their drug posed.
-
+1 +1
EpiPen rival to be offered free to many but high price for insurers
Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500. EpiPen maker Mylan NV came under intense criticism last year when it raised the price for a pair of its life-saving auto-injectors to $600, putting it out of reach for many consumers. It has since said it will sell its own generic EpiPen for about half that price.
Submit a link
Start a discussion